arrow
J

John L. Berk

Boston University School of Medicine
H指数:53
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients

Eplontersen用于遗传性甲状腺素转运蛋白淀粉样变性伴多发性神经病变:一项探索性分析治疗效应在男性和女性患者中的表现

2026-04-060
OAAI
Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis

神经病变损害与营养状况:eplontersen在遗传性甲状腺素转运蛋白介导的淀粉样变性患者中的应用

2025-10-280
PRE
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B

Vutrisiran对伴有心肌病的甲状腺素转运蛋白淀粉样变性患者心脏生物标志物的影响:来自HELIOS-B的研究

2025-08-040
OA
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform (vol 271, pg 6655, 2024)

从伊托塞森切换到艾普隆特塞森治疗遗传性甲状腺素转运蛋白介导的淀粉样变性伴多发性神经病变:NEURO-TTRansform(第271卷,第6655页,2024年)的分析

2025-02-030
OA
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2025-01-0213
PRE
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
2023-10-2685
OA
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy

Eplontersen用于遗传性甲状腺素蛋白淀粉样变性伴多发性神经病

2023-10-1744
OA
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

Eplontersen的开放标签3期研究neuro-ttransform中遗传性甲状腺素蛋白淀粉样变性多发性神经病 (attrv-pn) 患者的特征

2022-12-1626
OAAI